Desfechos de sobrevida de 5 anos do PACIFIC Trial: durvalumabe pós-quimioradioterapia no câncer de pulmão não pequenas células estágio III.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer – Journal of Clinical Oncology

Estudo original: Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC